Vertex announces publication of vx-548 positive phase 2, proof-of-concept results in new england journal of medicine

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced publication in the new england journal of medicine (nejm) of preclinical data and the results from its phase 2 proof-of-concept trials evaluating treatment with the selective, oral nav1.8 inhibitor vx-548 for acute pain following abdominoplasty and bunionectomy surgeries. “vx-548 preclinical studies demonstrated high selectivity and potency for the nav1.8 sodium channel which translated into phase 2 clin.
VRTX Ratings Summary
VRTX Quant Ranking